Skip to main content

Advertisement

Log in

Serum biomarkers for the diagnosis and monitoring of chronic recurrent multifocal osteomyelitis (CRMO)

  • Biomarkers
  • Published:
Rheumatology International Aims and scope Submit manuscript

Abstract

Chronic recurrent multifocal osteomyelitis (CRMO), the most severe form of chronic nonbacterial osteomyelitis, is an autoinflammatory bone disorder. A timely diagnosis and treatment initiation is complicated by the absence of widely accepted diagnostic criteria and an incomplete pathophysiological understanding. The aim of this study was to determine biomarkers for the diagnosis and follow-up of CRMO. Serum of 56 CRMO patients was collected at the time of diagnosis. As controls, sera from treatment-naïve age-matched patients with Crohn’s disease (N = 62) or JIA (N = 28) as well as healthy individuals (N = 62) were collected. Multiplex analysis of 25 inflammation markers was performed. Statistical analysis was performed using Kruskal–Wallis and Mann–Whitney U tests, canonical discriminant analysis, and mixed model variance analysis. Mostly monocyte-derived serum proteins were detectable and differed significantly between groups: IL-1RA, IL-2R, IL-6, IL-12, eotaxin, MCP-1, MIP-1b, RANTES. Multicomponent discriminant analysis allowed for the definition of algorithms differentiating between CRMO, Crohn’s disease, and healthy controls. Persistently high levels of MCP-1, IL-12, sIL-2R correlated with incomplete remission in follow-up samples from CRMO patients. Discrimination algorithms allow differentiation between patients with CRMO or Crohn’s disease, and healthy individuals. IL-12, MCP-1, and sIL-2R can act as markers for treatment response. Though confirmation of our findings in larger multiethnical cohorts is warranted, they may prove valuable to differentiate between otherwise healthy individuals or Crohn’s disease patients with “bone pain” and CRMO patients. The elevation of mainly monocyte-derived pro-inflammatory serum proteins supports the hypothesis of pro-inflammatory monocyte/macrophages driving inflammation in CRMO.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

Abbreviations

CNO:

Chronic nonbacterial osteomyelitis

CRMO:

Chronic recurrent multifocal osteomyelitis

CRP:

C-reactive protein

Eotaxin:

C-C motif chemokine 11, also known as eosinophil chemotactic protein and eotaxin-1

ESR:

Erythrocyte sedimentation rate

GM-CSF:

Granulocyte macrophage colony stimulating factor

IFN:

Interferon

IL:

Interleukin

IL-1RA:

IL-1 receptor antagonist

JIA:

Juvenile idiopathic arthritis

sIL-2R:

Soluble IL-2 receptor

IP-10:

Interferon gamma-induced protein 10, also known as C-X-C motif chemokine 10 (CXCL10)

MCP-1:

Monocyte chemotactic protein 1

MIG:

Monokine induced by gamma-interferon, also known as Chemokine (C-X-C motif) ligand 9 (CXCL9)

MIP:

Macrophage inflammatory protein

RANTES:

Regulated on activation, normal T cell expressed and secreted protein, also known as Chemokine (C-C motif) ligand 5 (CCL5)

TNF-α:

Tumor necrosis factor α

References

  1. Hedrich CM, Hahn G, Girschick HJ, Morbach H (2013) A clinical and pathomechanistic profile of chronic nonbacterial osteomyelitis/chronic recurrent multifocal osteomyelitis and challenges facing the field. Expert Rev Clin Immunol 9(9):845–854

    Article  PubMed  Google Scholar 

  2. Hedrich CM, Hofmann SR, Pablik J, Morbach H, Girschick HJ (2013) Autoinflammatory bone disorders with special focus on chronic recurrent multifocal osteomyelitis (CRMO). Pediatr Rheumatol Online J 11(1):47

    Article  PubMed  PubMed Central  Google Scholar 

  3. Stern SM, Ferguson PJ (2013) Autoinflammatory bone diseases. Rheum Dis Clin North Am 39(4):735–749

    Article  PubMed  Google Scholar 

  4. Chitu V, Ferguson PJ, de Bruijn R, Schlueter AJ, Ochoa LA, Waldschmidt TJ et al (2009) Primed innate immunity leads to autoinflammatory disease in PSTPIP2-deficient cmo mice. Blood 114(12):2497–2505

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Ferguson PJ, Bing X, Vasef MA, Ochoa LA, Mahgoub A, Waldschmidt TJ et al (2006) A missense mutation in pstpip2 is associated with the murine autoinflammatory disorder chronic multifocal osteomyelitis. Bone 38(1):41–47

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Chitu V, Nacu V, Charles JF, Henne WM, McMahon HT, Nandi S et al (2012) PSTPIP2 deficiency in mice causes osteopenia and increased differentiation of multipotent myeloid precursors into osteoclasts. Blood 120(15):3126–3135

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Grosse J, Chitu V, Marquardt A, Hanke P, Schmittwolf C, Zeitlmann L et al (2006) Mutation of mouse Mayp/Pstpip2 causes a macrophage autoinflammatory disease. Blood 107(8):3350–3358

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Hofmann SR, Roesen-Wolff A, Hahn G, Hedrich CM (2012) Update: cytokine dysregulation in chronic nonbacterial osteomyelitis (CNO). Int J Rheumatol 2012:310206

    Article  PubMed  PubMed Central  Google Scholar 

  9. Hofmann SR, Morbach H, Schwarz T, Rosen-Wolff A, Girschick HJ, Hedrich CM (2012) Attenuated TLR4/MAPK signaling in monocytes from patients with CRMO results in impaired IL-10 expression. Clin Immunol 145(1):69–76

    Article  CAS  PubMed  Google Scholar 

  10. Hamel J, Paul D, Gahr M, Hedrich CM (2012) Pilot study: possible association of IL10 promoter polymorphisms with CRMO. Rheumatol Int 32(2):555–556

    Article  CAS  PubMed  Google Scholar 

  11. Hofmann SR, Schwarz T, Moller JC, Morbach H, Schnabel A, Rosen-Wolff A et al (2011) Chronic non-bacterial osteomyelitis is associated with impaired Sp1 signaling, reduced IL10 promoter phosphorylation, and reduced myeloid IL-10 expression. Clin Immunol 141(3):317–327

    Article  CAS  PubMed  Google Scholar 

  12. Jansson AF, Muller TH, Gliera L, Ankerst DP, Wintergerst U, Belohradsky BH et al (2009) Clinical score for nonbacterial osteitis in children and adults. Arthritis Rheum 60(4):1152–1159

    Article  PubMed  Google Scholar 

  13. Girschick HJ, Zimmer C, Klaus G, Darge K, Dick A, Morbach H (2007) Chronic recurrent multifocal osteomyelitis: what is it and how should it be treated? Nat Clin Pract Rheumatol 3(12):733–738

    Article  PubMed  Google Scholar 

  14. Beck C, Morbach H, Beer M, Stenzel M, Tappe D, Gattenlohner S et al (2010) Chronic nonbacterial osteomyelitis in childhood: prospective follow-up during the first year of anti-inflammatory treatment. Arthritis Res Ther 12(2):R74

    Article  PubMed  PubMed Central  Google Scholar 

  15. McInnes IB (2013) Cytokines. In: Firestein GS Budd R, Harris Ed Jr (ed) Kelley´s textbook of rheumatology, 9th Edition. Elsevier Sanders, Philadelphia, pp 367–377

  16. Eulenfeld R, Dittrich A, Khouri C, Muller PJ, Mutze B, Wolf A et al (2012) Interleukin-6 signalling: more than Jaks and STATs. Eur J Cell Biol 91(6–7):486–495

    Article  CAS  PubMed  Google Scholar 

  17. Hamza T, Barnett JB, Li B (2010) Interleukin 12 a key immunoregulatory cytokine in infection applications. Int J Mol Sci 11(3):789–806

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Griffith JW, Sokol CL, Luster AD (2014) Chemokines and chemokine receptors: positioning cells for host defense and immunity. Annu Rev Immunol 32:659–702

    Article  CAS  PubMed  Google Scholar 

  19. Chen W, Paulus B, Shu D, Wilson I, Chadwick V (2001) Increased serum levels of eotaxin in patients with inflammatory bowel disease. Scand J Gastroenterol 36(5):515–520

    Article  CAS  PubMed  Google Scholar 

  20. Rehman MQ, Beal D, Liang Y, Noronha A, Winter H, Farraye FA et al (2013) B cells secrete eotaxin-1 in human inflammatory bowel disease. Inflamm Bowel Dis 19(5):922–933

    Article  PubMed  Google Scholar 

  21. Hofmann SR, Rosen-Wolff A, Tsokos GC, Hedrich CM (2012) Biological properties and regulation of IL-10 related cytokines and their contribution to autoimmune disease and tissue injury. Clin Immunol 143(2):116–127

    Article  CAS  PubMed  Google Scholar 

  22. Glocker EO, Kotlarz D, Klein C, Shah N, Grimbacher B (2011) IL-10 and IL-10 receptor defects in humans. Ann N Y Acad Sci 1246:102–107

    Article  CAS  PubMed  Google Scholar 

  23. Hedrich CM, Bream JH (2010) Cell type-specific regulation of IL-10 expression in inflammation and disease. Immunol Res 47(1–3):185–206

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Bruck N, Schnabel A, Hedrich CM (2015) Current understanding of the pathophysiology of systemic juvenile idiopathic arthritis (sJIA) and target-directed therapeutic approaches. Clin Immunol 159(1):72–83

    Article  CAS  PubMed  Google Scholar 

  25. Niehues T, Feyen O, Telieps T (2008) Concepts on the pathogenesis of juvenile idiopathic arthritis. Z Rheumatol 67(2):111–116

    Article  CAS  PubMed  Google Scholar 

  26. Hofmann SR, Kubasch AS, Ioannidis C, Rosen-Wolff A, Girschick HJ, Morbach H et al (2015) Altered expression of IL-10 family cytokines in monocytes from CRMO patients result in enhanced IL-1beta expression and release. Clin Immunol 161(2):300–307

    Article  CAS  PubMed  Google Scholar 

  27. Barranco C (2014) Experimental arthritis: link between IL-10 and activation of the NLRP3 inflammasome in the synovium. Nat Rev Rheumatol 10(10):576

    Article  PubMed  Google Scholar 

  28. Greenhill CJ, Jones GW, Nowell MA, Newton Z, Harvey AK, Moideen AN et al (2014) Interleukin-10 regulates the inflammasome-driven augmentation of inflammatory arthritis and joint destruction. Arthritis Res Ther 16(4):419

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgments

The authors thank Prof. Dr. Ezio Bonifacio and Carmen Wilhelm for their support during Luminex® analysis and Christine Hedrich for valuable discussion and editing of the manuscript.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Christian Michael Hedrich.

Ethics declarations

Compliance with ethical standards

C. M. H. participated in an advisory board meeting by Novartis Pharmaceuticals on the pathophysiology and treatment of systemic JIA. The authors declare that they have no competing interests. The authors declare no relevant financial conflict of interest relevant to this manuscript. The study was supported by the MeDDrive 2014 program, Faculty of Medicine Carl Gustav Carus, TU Dresden (Grant Number: 60.343), and the Novartis Foundation for Therapeutic Research (both grants to C.M.H.). All individuals and/or their parents or legal guardians gave written informed consent. Sample collection and use were approved by the ethics committees of the University of Würzburg (CRMO, JIA patients, and controls) and the University of Technology Dresden/Technische Universität Dresden (Crohn’s disease).

Additional information

Sigrun Renate Hofmann and Anne Sophie Kubasch have contributed equally to this work.

Electronic supplementary material

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hofmann, S.R., Kubasch, A.S., Range, U. et al. Serum biomarkers for the diagnosis and monitoring of chronic recurrent multifocal osteomyelitis (CRMO). Rheumatol Int 36, 769–779 (2016). https://doi.org/10.1007/s00296-016-3466-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00296-016-3466-7

Keywords

Navigation